Politics
Tomorrow, three distinguished pharmaceutical firm CEOs will testify earlier than the Senate, together with Johnson & Johnson. The listening to held by the Senate Well being Committee is to debate the astronomically excessive costs Individuals are compelled to pay for crucial drugs for continual sicknesses.
Undoubtedly, testimony will contact on the pending lawsuits filed by the identical firms to halt federally mandated Medicare negotiations with the businesses to decrease mentioned drug costs. Due to the Inflation Discount Act, Medicare has been given the authority to barter the costs down for important drugs, a lot to the ire of massive Pharma.
One of the simplest ways to know the difficulty of sky-high medicine prices for Individuals and the pending litigation over Medicare negotiations is to flashback to late final 12 months when Congressman Ro Khanna grilled Johnson & Johnson Assistant Basic Counsel Aviva Wein.
Making financial institution
Late final 12 months, Aviva Wein, the assistant normal counsel for Johnson & Johnson, testified earlier than Congress on the difficulty of decreasing drug costs for Individuals. Ms. Wein didn’t financial institution on Congressman Ro Khanna coming with some onerous numbers and what ought to’ve been a straightforward query for her to reply.
Congressman Khanna used the leukemia medicine Imbruvica to show a degree in regards to the staggering price of crucial medicine for blood most cancers. Unsurprisingly, Ms. Wein didn’t know the main points of how a lot Imbruvica prices, however Congressman Khanna was capable of educate her.
He laid out that the price of one pill of Imbruvica prices $484 which equates to roughly $14,000 per thirty days of medicine. For one 12 months of medicine, it prices a blood most cancers affected person $160,000.
RELATED: Washington State Gave $340 Million In Covid Funds To Unlawful Aliens
When requested, Ms. Wein couldn’t present the general income that has introduced her employer, however once more Congressman Khanna didn’t disappoint. He defined that Johnson & Johnson has made $22 billion off of Imbruvica over the past ten years.
General, for 2023, Congressman Khanna let Ms. Wein know that the corporate she represents made $65 billion. After laying out how nicely Johnson & Johnson does off of Imbruvica, issues received attention-grabbing.
A easy query
Johnson & Johnson, amongst different pharmaceutical firms, is suing the federal authorities over the Inflation Discount Act’s requirement that Medicare attempt to negotiate down the value of medicines identical to Imbruvica. The lawsuit from Johnson & Johnson claims that this negotiation constitutions an “unjust taking.”
The lawsuit is referencing the Fifth Modification’s ‘Takings Clause’ which states:
“Nor shall private property be taken for public use, without just compensation.”
Basically, the argument is the federal authorities is taking drugs like Imbruvica from the corporate that creates it to offer to the general public with out offering applicable cost. Keep in mind, Johnson & Johnson at the moment makes $160,000 a 12 months per blood most cancers affected person who purchases their medicine.
Congressman Khanna requested Ms. Wein:
“Do you believe when the Veterans Administration negotiates for drug prices with you that that is a violation of the Takings Clause?”
RELATED: Farmer Protests in Europe Foreshadow Darkish Future for American Farmers
Simply as with each query Congressman Khanna requested, Ms. Wein couldn’t reply. To which Congressman Khanna rightly identified the absurdity of her incapability:
“You’re here, you’re the assistant general counsel for a company accusing the US government of taking your property because we’re negotiating drug prices, and you can’t answer a simple question…”
Seems like an terrible lot like another Congressional listening to on another matter.
The purpose
Tomorrow, Merck, Johnson & Johnson, and Bristol Myers Squibb’s CEOs will testify on the Senate Well being Committee listening to on drug costs. Whereas the CEO of Bristol Myers Squibb had freely accepted his invitation to testify, it took the specter of subpoena for the CEOs of Merck and Johnson & Johnson to agree.
Had the Senate Well being Committee issued the subpoenas, it could’ve been the primary time in 40 years for the reason that committee has had to make use of such a tactic. Of be aware, the next drugs are on the checklist for negotiation with Medicare:
- Merck’s diabetes drug Januvia
- Johnson & Johnson’s blood most cancers therapy drug Imbruvica
- Myers Squibb’s blood thinner Eliquis
The problem isn’t simply that these medication are costly and have a considerably increased unfavorable impression for these on Medicare particularly. The purpose is that it’s costlier to buy nearly each medicine in the USA than wherever else on the planet.
For instance:
- Merck’s Januvia checklist value is $6,900 in the USA – $200 in France
- Johnson & Johnson’s psoriasis drug Stelara checklist value is $79,000 in the USA – $16,000 in the UK
- Myers Squibb’s Eliquis checklist value is $7,100 in the USA – $650 in France
Why is it so costly for Individuals affected by continual sickness to buy the drugs they want than it’s for the French and the British? Why is it a problem for Medicare to barter for decrease costs than for the VA?
My cash is that none of these questions will probably be answered tomorrow, however they each deserve a solution. However one factor is for certain: it wasn’t way back that these similar firms, specifically Johnson & Johnson, had been hailed as heroes for pushing by way of an experimental vaccine.
The political elite have brief reminiscences; let’s hope those that elected them of their seats remind them of the long-fought battle with massive Pharma.
Now could be the time to assist and share the sources you belief.
The Political Insider ranks #3 on Feedspot’s “100 Best Political Blogs and Websites.”